Ticker Details
4D Molecular Therapeutics, Inc.
IPO Date:	December 11, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$874.52M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.64 | 3.90%
Avg Daily Range (30 D):	$0.53 | 4.48%
Avg Daily Range (90 D):	$0.44 | 4.16%

Institutional Daily Volume
Avg Daily Volume:	.47M
Avg Daily Volume (30 D):	.67M
Avg Daily Volume (90 D):	.68M

Trade Size
Avg Trade Size (Sh.):	75
Avg Trade Size (Sh.) (30 D):	67
Avg Trade Size (Sh.) (90 D):	67

Institutional Trades
Total Institutional Trades:	1,293
Avg Institutional Trade:	$1.79M
Avg Institutional Trade (30 D):	$1.45M
Avg Institutional Trade (90 D):	$1.79M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.71M
Avg Closing Trade (30 D):	$1.41M
Avg Closing Trade (90 D):	$1.43M
Avg Closing Volume:	108.02K

News

Jul 18, 2026 @ 7:15 PM 4DMT Announces Positive 2-Year Data from PRISM Pha... Source: Not Specified

Jun 29, 2026 @ 12:00 PM 4DMT Secures Strategic Credit Facility for up to $... Source: Na

Jun 18, 2026 @ 5:00 PM Age-related Macular Degeneration Clinical Trial Pi... Source: Delveinsight

Feb 19, 2026 @ 1:00 PM 4DMT to Participate in Upcoming Investor Conferenc... Source: Na

Nov 17, 2025 @ 11:00 AM 4DMT Appoints Kristian Humer as Chief Financial Of... Source: 4D Molecular Therapeutics

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-2.63	$-1.04	$-1.01
Diluted EPS	$-2.63	$-1.04	$-1.01
Revenue	$92.01M	$3.78M	$3.05M
Gross Profit
Net Income / Loss	$-179.18M	$-72.94M	$-68.76M
Operating Income / Loss	$-197.12M	$-77.03M	$-73.62M
Cost of Revenue
Net Cash Flow	$-6.79M	$-2.12M	$12.25M
PE Ratio